Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy
Clin. transl. oncol. (Print)
; 24(2): 371-378, febrero 2022.
Article
in English
| IBECS
| ID: ibc-203442
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
BackgroundPatients with prostate-specific antigen (PSA) persistence are at the increased risk of disease progression. The aim of our study was to evaluate the impact of early salvage therapy on oncological outcomes in patients with persistent PSA after radical prostatectomy (RP).MethodsWithin a single tertiary centre database, we identified men with persistent (≥ 0.1 ng/ml) versus undetectable (< 0.1 ng/ml) PSA 48 weeks after RP for high-risk prostate cancer (HRPCa). The cumulative incidence function was used to estimate cancer-specific survival (CSS) and clinical progression-free survival (CPFS). The KaplanMeier method was used to estimate overall survival (OS). The effects on oncological outcomes of salvage radiotherapy (SRT) ± androgen deprivation therapy (ADT) vs. ADT monotherapy were tested in the subgroup of patients with persistent PSA.ResultsOf 414 consecutive patients who underwent RP for HRPC, 125 (30.2%) had persistent PSA. Estimated 10-year CPFS, CSS and OS for men with persistent vs. undetectable PSA were 63.8% vs. 93.5%, 78.5% vs. 98.3% and 54% vs. 83.2% (all p < 0.0001), respectively. In men with persistent PSA, ADT alone was associated with higher risk (hazard ratio (HR) for worse CSS (HR 3.9, p = 0.005) and OS (HR 4.7, p < 0.0001) but not for CP (HR 1.6, p = 0.2) when compared with SRT ± ADT.ConclusionIn patients who underwent RP for HRPCa, persistent PSA was associated with poor oncological outcomes. Early SRT ± ADT resulted in significantly improved CSS and OS in men with persistent PSA comparing with early androgen deprivation monotherapy.
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Prostatectomy
/
Prostatic Neoplasms
/
Prostate-Specific Antigen
/
Health Sciences
/
Androgens
Limits:
Humans
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2022
Document type:
Article
Institution/Affiliation country:
Leuven Biostatistics and Statistical Bioinformatics Center/Belgium
/
Lithuanian University of Health Sciences/Lithuania
/
University Hospitals Leuven/Belgium